Logo image of AIM

AIM IMMUNOTECH INC (AIM) Stock Fundamental Analysis

NYSEARCA:AIM - NYSE Arca - US00901B1052 - Common Stock - Currency: USD

9.25  +0.6 (+6.87%)

Fundamental Rating

1

Taking everything into account, AIM scores 1 out of 10 in our fundamental rating. AIM was compared to 558 industry peers in the Biotechnology industry. AIM may be in some trouble as it scores bad on both profitability and health. AIM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AIM had negative earnings in the past year.
In the past year AIM has reported a negative cash flow from operations.
In the past 5 years AIM always reported negative net income.
In the past 5 years AIM always reported negative operating cash flow.
AIM Yearly Net Income VS EBIT VS OCF VS FCFAIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -243.41%, AIM is not doing good in the industry: 91.22% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -243.41%
ROE N/A
ROIC N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIM Yearly ROA, ROE, ROICAIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 77.40%, AIM belongs to the top of the industry, outperforming 84.41% of the companies in the same industry.
AIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIM Yearly Profit, Operating, Gross MarginsAIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AIM has more shares outstanding than it did 1 year ago.
AIM has less shares outstanding than it did 5 years ago.
AIM has a worse debt/assets ratio than last year.
AIM Yearly Shares OutstandingAIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AIM Yearly Total Debt VS Total AssetsAIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -106.76, we must say that AIM is in the distress zone and has some risk of bankruptcy.
AIM's Altman-Z score of -106.76 is on the low side compared to the rest of the industry. AIM is outperformed by 96.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -106.76
ROIC/WACCN/A
WACC9.48%
AIM Yearly LT Debt VS Equity VS FCFAIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.26 indicates that AIM may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.26, AIM is doing worse than 93.91% of the companies in the same industry.
AIM has a Quick Ratio of 0.26. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.26, AIM is not doing good in the industry: 93.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.26
AIM Yearly Current Assets VS Current LiabilitesAIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

AIM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2260.00%.
AIM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.35%.
AIM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.96% yearly.
EPS 1Y (TTM)-2260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4066.67%
Revenue 1Y (TTM)-24.35%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-60%

3.2 Future

Based on estimates for the next years, AIM will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.52% on average per year.
AIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 281.45% yearly.
EPS Next Y96.54%
EPS Next 2Y39.81%
EPS Next 3Y24.88%
EPS Next 5Y15.52%
Revenue Next Year37.93%
Revenue Next 2Y17.44%
Revenue Next 3Y306.65%
Revenue Next 5Y281.45%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AIM Yearly Revenue VS EstimatesAIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AIM Yearly EPS VS EstimatesAIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIM Price Earnings VS Forward Price EarningsAIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIM Per share dataAIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as AIM's earnings are expected to grow with 24.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.81%
EPS Next 3Y24.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AIM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AIM IMMUNOTECH INC

NYSEARCA:AIM (7/18/2025, 8:04:00 PM)

9.25

+0.6 (+6.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-14 2025-08-14
Inst Owners6.32%
Inst Owner Change0%
Ins Owners11.56%
Ins Owner Change13.34%
Market Cap7.03M
Analysts80
Price Target153 (1554.05%)
Short Float %1.44%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.01%
Min EPS beat(2)13.9%
Max EPS beat(2)38.12%
EPS beat(4)4
Avg EPS beat(4)39.14%
Min EPS beat(4)13.9%
Max EPS beat(4)67.89%
EPS beat(8)5
Avg EPS beat(8)5.95%
EPS beat(12)7
Avg EPS beat(12)1.49%
EPS beat(16)7
Avg EPS beat(16)-5.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5354.55%
PT rev (3m)5354.55%
EPS NQ rev (1m)-8788.89%
EPS NQ rev (3m)-8788.89%
EPS NY rev (1m)5.41%
EPS NY rev (3m)5.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-92.31%
Revenue NY rev (3m)-92.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 48.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.1
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-16.46
FCFYN/A
OCF(TTM)-16.36
OCFYN/A
SpS0.19
BVpS-5.07
TBVpS-8.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -243.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.4%
FCFM N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.26
Altman-Z -106.76
F-Score4
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)119.66%
Cap/Depr(5y)104.37%
Cap/Sales(3y)164.13%
Cap/Sales(5y)265.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4066.67%
EPS Next Y96.54%
EPS Next 2Y39.81%
EPS Next 3Y24.88%
EPS Next 5Y15.52%
Revenue 1Y (TTM)-24.35%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-60%
Revenue Next Year37.93%
Revenue Next 2Y17.44%
Revenue Next 3Y306.65%
Revenue Next 5Y281.45%
EBIT growth 1Y47.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.99%
OCF growth 3YN/A
OCF growth 5YN/A